• Je něco špatně v tomto záznamu ?

CLCN1 mutations in Czech patients with myotonia congenita, in silico analysis of novel and known mutations in the human dimeric skeletal muscle chloride channel

D. Skálová, J. Zídková, S. Voháňka, R. Mazanec, Z. Mušová, P. Vondráček, L. Mrázová, J. Kraus, K. Réblová, L. Fajkusová,

. 2013 ; 8 (12) : e82549.

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc15008452

Grantová podpora
NT14574 MZ0 CEP - Centrální evidence projektů

Myotonia congenita (MC) is a genetic disease caused by mutations in the skeletal muscle chloride channel gene (CLCN1) encoding the skeletal muscle chloride channel (ClC-1). Mutations of CLCN1 result in either autosomal dominant MC (Thomsen disease) or autosomal recessive MC (Becker disease). The ClC-1 protein is a homodimer with a separate ion pore within each monomer. Mutations causing recessive myotonia most likely affect properties of only the mutant monomer in the heterodimer, leaving the wild type monomer unaffected, while mutations causing dominant myotonia affect properties of both subunits in the heterodimer. Our study addresses two points: 1) molecular genetic diagnostics of MC by analysis of the CLCN1 gene and 2) structural analysis of mutations in the homology model of the human dimeric ClC-1 protein. In the first part, 34 different types of CLCN1 mutations were identified in 51 MC probands (14 mutations were new). In the second part, on the basis of the homology model we identified the amino acids which forming the dimer interface and those which form the Cl(-) ion pathway. In the literature, we searched for mutations of these amino acids for which functional analyses were performed to assess the correlation between localisation of a mutation and occurrence of a dominant-negative effect (corresponding to dominant MC). This revealed that both types of mutations, with and without a dominant-negative effect, are localised at the dimer interface while solely mutations without a dominant-negative effect occur inside the chloride channel. This work is complemented by structural analysis of the homology model which provides elucidation of the effects of mutations, including a description of impacts of newly detected missense mutations.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc15008452
003      
CZ-PrNML
005      
20181030135346.0
007      
ta
008      
150306s2013 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1371/journal.pone.0082549 $2 doi
035    __
$a (PubMed)24349310
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Skálová, Daniela $u Centre of Molecular Biology and Gene Therapy, University Hospital, Brno, Brno, Czech Republic ; Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
245    10
$a CLCN1 mutations in Czech patients with myotonia congenita, in silico analysis of novel and known mutations in the human dimeric skeletal muscle chloride channel / $c D. Skálová, J. Zídková, S. Voháňka, R. Mazanec, Z. Mušová, P. Vondráček, L. Mrázová, J. Kraus, K. Réblová, L. Fajkusová,
520    9_
$a Myotonia congenita (MC) is a genetic disease caused by mutations in the skeletal muscle chloride channel gene (CLCN1) encoding the skeletal muscle chloride channel (ClC-1). Mutations of CLCN1 result in either autosomal dominant MC (Thomsen disease) or autosomal recessive MC (Becker disease). The ClC-1 protein is a homodimer with a separate ion pore within each monomer. Mutations causing recessive myotonia most likely affect properties of only the mutant monomer in the heterodimer, leaving the wild type monomer unaffected, while mutations causing dominant myotonia affect properties of both subunits in the heterodimer. Our study addresses two points: 1) molecular genetic diagnostics of MC by analysis of the CLCN1 gene and 2) structural analysis of mutations in the homology model of the human dimeric ClC-1 protein. In the first part, 34 different types of CLCN1 mutations were identified in 51 MC probands (14 mutations were new). In the second part, on the basis of the homology model we identified the amino acids which forming the dimer interface and those which form the Cl(-) ion pathway. In the literature, we searched for mutations of these amino acids for which functional analyses were performed to assess the correlation between localisation of a mutation and occurrence of a dominant-negative effect (corresponding to dominant MC). This revealed that both types of mutations, with and without a dominant-negative effect, are localised at the dimer interface while solely mutations without a dominant-negative effect occur inside the chloride channel. This work is complemented by structural analysis of the homology model which provides elucidation of the effects of mutations, including a description of impacts of newly detected missense mutations.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a chloridové kanály $x chemie $x genetika $x metabolismus $7 D018118
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a molekulární modely $7 D008958
650    _2
$a kosterní svaly $x metabolismus $7 D018482
650    12
$a mutace $7 D009154
650    _2
$a missense mutace $7 D020125
650    _2
$a myotonia congenita $x diagnóza $x genetika $7 D009224
650    _2
$a fenotyp $7 D010641
650    _2
$a konformace proteinů $7 D011487
650    _2
$a multimerizace proteinu $7 D055503
650    _2
$a mladý dospělý $7 D055815
651    _2
$a Česká republika $7 D018153
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Zídková, Jana $u Centre of Molecular Biology and Gene Therapy, University Hospital, Brno, Brno, Czech Republic ; Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
700    1_
$a Voháňka, Stanislav $u Department of Neurology, University Hospital Brno, Brno, Czech Republic. $7 xx0060520
700    1_
$a Mazanec, Radim, $u Department of Neurology, Charles University Second Faculty of Medicine and University Hospital Motol, Prague, Czech Republic. $d 1959- $7 xx0037204
700    1_
$a Mušová, Zuzana $u Department of Biology and Medical Genetics, Charles University Second Faculty of Medicine and University Hospital Motol, Prague, Czech Republic. $7 xx0082031
700    1_
$a Vondráček, Petr $u Department of Child Neurology, University Hospital Brno, Brno, Czech Republic. $7 _AN074948
700    1_
$a Mrázová, Lenka $u Department of Child Neurology, University Hospital Brno, Brno, Czech Republic. $7 xx0200910
700    1_
$a Kraus, Josef, $u Department of Child Neurology, Second School of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic. $d 1951- $7 mzk2004261109
700    1_
$a Réblová, Kamila $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic. $7 _AN035442
700    1_
$a Fajkusová, Lenka, $u Centre of Molecular Biology and Gene Therapy, University Hospital, Brno, Brno, Czech Republic ; Central European Institute of Technology, Masaryk University, Brno, Czech Republic. $d 1963- $7 xx0062747
773    0_
$w MED00180950 $t PloS one $x 1932-6203 $g Roč. 8, č. 12 (2013), s. e82549
856    41
$u https://pubmed.ncbi.nlm.nih.gov/24349310 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20150306 $b ABA008
991    __
$a 20181030135903 $b ABA008
999    __
$a ok $b bmc $g 1065725 $s 891252
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2013 $b 8 $c 12 $d e82549 $i 1932-6203 $m PLoS One $n PLoS One $x MED00180950
GRA    __
$a NT14574 $p MZ0
LZP    __
$a Pubmed-20150306

Najít záznam

Citační ukazatele

    Možnosti archivace